[Clinical evaluation of the use of proglumide in the treatment of the peptic ulcer semebrome].
The authors have made a clinical evaluation of Proglumida in 27 patients suffering from Peptic ulcer. Proglumida was administered orraly, 2 tables of 200 mg 3 times a day, 1.200 mg in 24 hours, during a period varying from 21 to 28 days. The painful symptoms improved in 96% of the pain occurred in 59% during the first 7 days of treatment. The dispeptic symptoms improved in all cases, disappearing completely in 74%, but in a slower fashion than the pain, and in 68% of the cases only from the second week of treatment onward. The objectivation of the pain by palpation of the epigastrium improved in all cases and did so in a significant form in 59% of the cases during the first seven days of treatment. No undesireable side effects have been observed in any of the cases. We believe that Proglumida is a pharmacological drug of positive action in the treatment of the ulcer syndrome, because of its favorable action and the absence of secondary side effects.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004381:Duodenal Ulcer / Q000188:drug therapy*; D005260:Female; D005973:Glutamine / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011377:Proglumide / Q000627:therapeutic use*; D013276:Stomach Ulcer / Q000188:drug therapy*; D013607:Tablets
D013607:Tablets; D005973:Glutamine; D011377:Proglumide
Valoración clínica del uso de la proglumida en el tratamiento del sindrome ulceroso